Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shigeo Fuji & Akihiro Ohmoto. (2022) Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. Expert Review of Hematology 15:1, pages 45-51.
Read now
Read now
Sylvain Garciaz, Mickael Loschi, Adèle De Masson, Lucie Biard, Mélanie Mercier, Cécile Tomowiak, Jeremy Delage, Hélène Labussiere-Wallet, David Sibon, Ophélie Cassuto, Cécile Borel, Jérome Cornillon, Stanislas Nimubona, Amandine Charbonnier, Pauline Brice, Gérard Socié, Reda Bouabdallah, Régis Peffault de Latour & Flore Sicre de Fontbrune. (2019) Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. Leukemia & Lymphoma 60:11, pages 2802-2805.
Read now
Read now
Eunhye Oak & Nancy L. Bartlett. (2016) A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety 15:6, pages 875-882.
Read now
Read now
Reyad Dada, Jamal Zekri & Rawan Al Saadi. (2016) Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opinion on Biological Therapy 16:6, pages 739-745.
Read now
Read now
Massimo Martino, Moreno Festuccia, Roberta Fedele, Giuseppe Console, Michele Cimminiello, Paolo Gavarotti & Benedetto Bruno. (2016) Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. Expert Opinion on Biological Therapy 16:3, pages 347-364.
Read now
Read now
Michelle Furtado, Kathleen Clarke, Patrick Medd, Hannah Hunter & Simon Rule. (2016) The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. Leukemia & Lymphoma 57:2, pages 461-462.
Read now
Read now
Articles from other publishers (19)
Muhammad Salman Faisal, Walter Hanel, Timothy Voorhees, Rui Li, Ying Huang, Abdullah Khan, David Bond, Yazeed Sawalha, John Reneau, Lapo Alinari, Robert Baiocchi, Beth Christian, Kami Maddocks, Yvonne Efebera, Sam Penza, Ayman Saad, Jonathan Brammer, Marcos DeLima, Samantha Jaglowski & Narendranath Epperla. (2023) Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine 12:7, pages 8228-8237.
Crossref
Crossref
Fateeha Furqan, Kwang W. Ahn, Yue Chen, Manmeet Kaur, Syed A. Abutalib, Nausheen Ahmed, Sairah Ahmed, Mohamed A. Kharfan‐Dabaja, Johnathan Friedberg, Tara Gregory, LaQuisa Hill, Cole Sterling, Stephan K. Barta, Mazyar Shadman, Miguel‐Angel Perales, Jasmine Zain, Alex F. Herrera, Craig Sauter & Mehdi Hamadani. (2022) Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. British Journal of Haematology 200:1, pages 54-63.
Crossref
Crossref
H. Miles Prince, Martin Hutchings, Eva Domingo-Domenech, Dennis A. Eichenauer & Ranjana Advani. (2022) Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Annals of Hematology 102:1, pages 13-29.
Crossref
Crossref
M. N. Korsantya, Y. E. Romankova, N. V. Myakova & A. V. Pshonkin. (2020) The experience of using the Brentuximab vedotin in the treatment of children and young adults with primary refractory course and relapses of Hodgkin's lymphoma. Pediatric Hematology/Oncology and Immunopathology 19:1, pages 47-52.
Crossref
Crossref
E. Domingo-Domènech, A. Boumendil, F. Climent, G. Socié, F. Kroschinsky, H. Finel, E. Vandenbergue, D. Nemet, M. Stelljes, J. T. Bittenbring, S. Robinson, S. Montoto, A. Sureda & P. Dreger. (2019) Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation 55:3, pages 633-640.
Crossref
Crossref
Kenichi Ishizawa & Tomoko Yanai. (2019) Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma. Advances in Therapy 36:10, pages 2679-2696.
Crossref
Crossref
Alina Mititelu, Elena Andruş-Lupoaia, Minodora- Cezarina Onisâi, Andreea Spînu, Camelia Dobre, Alina Tănase, Dragoş Bumbăcea & Ana Maria Vlădăreanu. (2019) A challenging case of relapsed refractory classical Hodgkin’s lymphoma – nodular sclerosis. Oncolog-Hematolog.ro 1:46, pages 36.
Crossref
Crossref
Alison J. Moskowitz. (2018) Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Hematology 2018:1, pages 207-212.
Crossref
Crossref
Ali Bazarbachi, Ariane Boumendil, Hervé Finel, Mohamad Mohty, Luca Castagna, Karl S. Peggs, Didier Blaise, Boris Afanasyev, José L. Diez-Martin, Jorge Sierra, Adrian Bloor, Carmen Martinez, Stephen Robinson, Ram Malladi, Jean El-Cheikh, Paolo Corradini, Silvia Montoto, Peter Dreger & Anna Sureda. (2018) Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. British Journal of Haematology 181:1, pages 86-96.
Crossref
Crossref
Eileen P. Smith, Hongli Li, Jonathan W. Friedberg, Louis S. Constine, Lisa M. Rimsza, James R. Cook, Ginna G. Laport, Leslie L. Popplewell, Leona A. Holmberg, Sonali M. Smith, Michael LeBlanc, Stephen J. Forman, Richard I. Fisher & Patrick J. Stiff. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biology of Blood and Marrow Transplantation 24:4, pages 700-707.
Crossref
Crossref
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani & Pier Luigi Zinzani. (2017) Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget 8:53, pages 91703-91710.
Crossref
Crossref
Luis Mario Villela-Ma, Ana Karen Velez-Ayal, Rosa del Carmen Lopez-Sanc, Jorge A Martinez-C & Jose A Hernandez-. (2017) Advantages of Drug Selective Distribution in Cancer Treatment: Brentuximab Vedotin. International Journal of Pharmacology 13:7, pages 785-807.
Crossref
Crossref
Helen Ma & Maher Abdul-Hay. (2016) T-cell lymphomas, a challenging disease: types, treatments, and future. International Journal of Clinical Oncology 22:1, pages 18-51.
Crossref
Crossref
Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya & Olga V. Aleinikova. (2017) Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma. Journal of Cancer Therapy 08:08, pages 683-690.
Crossref
Crossref
Letizia Gandolfi, Cinzia Pellegrini, Beatrice Casadei, Vittorio Stefoni, Alessandro Broccoli, Lorenzo Tonialini, Alice Morigi, Lisa Argnani & Pier Luigi Zinzani. (2016) Long‐Term Responders After Brentuximab Vedotin: Single‐Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. The Oncologist 21:12, pages 1436-1441.
Crossref
Crossref
. (2016) Brentuximab-vedotin. Reactions Weekly 1600:1, pages 60-60.
Crossref
Crossref
A Rashidi, M Ebadi & A F Cashen. (2016) Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplantation 51:4, pages 521-528.
Crossref
Crossref
Esmeralda Chi-yuan Teo, Yveline Chew & Colin Phipps. (2016) A review of monoclonal antibody therapies in lymphoma. Critical Reviews in Oncology/Hematology 97, pages 72-84.
Crossref
Crossref
Natalia Myakova, Nadezhda Smirnova, Dmitry Evstratov, Yulia Abugova, Dmitry Balashov, Yulia Diakonova, Dmitry Konovalov, Yulia Skvortsova & Alexey Maschan. (2015)
Brentuximab vedotin in the treatment of a patient with refractory
H
odgkin disease and
P
roteus syndrome – a case report and discussion
. Clinical Case Reports 3:7, pages 646-649.
Crossref
Crossref